DIANE HORAN
Prescription History 1992787220
Nurse Practitioner - Adult Health in East Bridgewater, MA
NPI Status: Active since November 14, 2005
Contact Information
1 COMPASS WAY STE 208
EAST BRIDGEWATER, MA
ZIP 02333
Phone: (508) 350-2222
Fax: (508) 350-2316
Prescription History for Informed Healthcare Decisions
Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for DIANE HORAN, an active Adult Health specialist practicing in East Bridgewater, MA. Our medical registry currently tracks 2 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 46 documented patient claims. Among these therapy options, the most frequently utilized medication is Hydroxyurea, which accounts for 31 claims alone.
Hydroxyurea
Generic Formulation: HydroxyureaSpecialty: Nurse PractitionerProvider Avg Cost Per Claim
$18.44
State Avg Cost Per Claim
$35.78
Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.
An antineoplastic agent that inhibits DNA synthesis through the inhibition of ribonucleoside diphosphate reductase.
This medication is used by people with sickle cell anemia to reduce the number of painful crises caused by the disease and to reduce the need for blood transfusions. Some brands are also used to treat certain types of cancer (such as chronic myelogenous leukemia, squamous cell carcinomas).
Xarelto
Generic Formulation: RivaroxabanSpecialty: Nurse PractitionerProvider Avg Cost Per Claim
$892.54
State Avg Cost Per Claim
$930.26
Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.
A morpholine and thiophene derivative that functions as a FACTOR XA INHIBITOR and is used in the treatment and prevention of DEEP-VEIN THROMBOSIS and PULMONARY EMBOLISM. It is also used for the prevention of STROKE and systemic embolization in patients with non-valvular ATRIAL FIBRILLATION, and for the prevention of atherothrombotic events in patients after an ACUTE CORONARY SYNDROME.
Rivaroxaban is used to prevent blood clots from forming due to a certain irregular heartbeat (atrial fibrillation) or after hip or knee replacement surgery. It is also used to prevent blood clots from forming in high-risk patients with limited mobility during their hospital stay and after discharge. In addition, rivaroxaban is used to treat blood clots (such as in deep vein thrombosis-DVT or pulmonary embolus-PE) and to prevent the blood clots from forming again. Rivaroxaban may be used in children to prevent blood clots from forming after a certain heart surgery (Fontan procedure). Rivaroxaban is an anticoagulant that works by blocking certain clotting proteins in your blood.
Dataset Methodology & CMS Source Information
This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like DIANE HORAN provides transparency into local medical care patterns within East Bridgewater, MA.
Key Learning Objectives for this Profile:
- Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
- Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Adult Health** practice concentrations.
- Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
- Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.
Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.
